ArticleFrontiers in oncology2025
Prospective evaluation of chemotherapy-induced dyslipidemia in early breast cancer: implications for cardiovascular risk.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06958783 (Detection of Changes in the Lipid Profile in Early-Stage Breast Cancer Patients Undergoing Neoadjuvant or Adjuvant Chemotherapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Detection of Changes in the Lipid Profile in Early-Stage Breast Cancer Patients Undergoing Neoadjuvant or Adjuvant Chemotherapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease is a leading cause of long-term mortality among breast cancer survivors, yet chemotherapy-induced dyslipidemia remains an underrecognized component of survivorship care. Methods: In this prospective, single-center study, 56 women with clinical stage IB-IIIB early breast cancer received standardized anthracycline- and taxane-based chemotherapy. Fasting lipid profiles including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, and triglycerides, were assessed at four timepoints: baseline, post-anthracycline-cyclophosphamide phase, end of treatment, and 3-month follow-up. Longitudinal changes were analysed using non-parametric tests and multivariable linear regression. Results: Baseline dyslipidemia was present in 78.4% of patients. Chemotherapy significantly altered all lipid parameters, with changes in total cholesterol ( Conclusion: Standard chemotherapy induces sustained proatherogenic lipid shifts in women with early breast cancer, independent of baseline cardiovascular risk factors. The unexpectedly high prevalence of dyslipidemia among premenopausal women challenges traditional assumptions of cardiometabolic protection in younger patients. These findings support the integration of lipid monitoring and early cardiovascular risk management into survivorship care. Clinical Trial Registration: NCT06958783, https://clinicaltrials.gov/study/NCT06958783.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.